Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Barrett

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|July 22, 2020
Reply to: Exercise for "Sleep Rehabilitation" in Parkinson's DiseaseAmy W Amara, Kimberly H Wood, Allen Joop, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 25, 2020
Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's DiseaseAmy W Amara, Kimberly H Wood, Allen Joop, et al.
Therapeutic Advances in Neurological Disorders|April 24, 2026
Efficacy and safety of apomorphine in the treatment of Parkinson's disease: a systematic review and meta-analysis of randomized controlled trialsMoaz Elsayed Abouelmagd, Abdallah Abbas, Obai Yousef, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|February 10, 2016
Glucocerebrosidase enzyme activity in GBA mutation Parkinson's diseaseRoberto A Ortega, Paola A Torres, Matthew Swan, et al.
Drugs & Aging|October 19, 2023
Low-Income Older Adults' Vulnerability to Anticholinergic Medication-Associated FrailtyLana Sargent, Kristin M Zimmerman, Almutairi Mohammed, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 16, 2024
The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodiesKathryn A Wyman-Chick, Matthew J Barrett, Michael J Miller, et al.
CNS Neuroscience & Therapeutics|August 4, 2024
Determining the role of statins in Parkinson's disease risk reduction and disease modification: A comprehensive meta-analysis of 4 million participants' dataAbdelrahman Mady, Yehia Nabil, Asma Daoud, et al.
Systematic Reviews|November 4, 2025
Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trialsMoaz Elsayed Abouelmagd, Nereen A Almosilhy, Hamdy A Makhlouf, et al.
Annals of Clinical and Translational Neurology|April 15, 2020
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson diseaseDaniel Weintraub, Chelsea Caspell-Garcia, Tanya Simuni, et al.
Neurology and Therapy|May 8, 2024
Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for CliniciansKathryn A Wyman-Chick, Parichita Chaudhury, Ece Bayram, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Movement Disorders : Official Journal of the Movement Disorder Society|July 22, 2020
Reply to: Exercise for "Sleep Rehabilitation" in Parkinson's DiseaseAmy W Amara, Kimberly H Wood, Allen Joop, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 25, 2020
Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's DiseaseAmy W Amara, Kimberly H Wood, Allen Joop, et al.
Therapeutic Advances in Neurological Disorders|April 24, 2026
Efficacy and safety of apomorphine in the treatment of Parkinson's disease: a systematic review and meta-analysis of randomized controlled trialsMoaz Elsayed Abouelmagd, Abdallah Abbas, Obai Yousef, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|February 10, 2016
Glucocerebrosidase enzyme activity in GBA mutation Parkinson's diseaseRoberto A Ortega, Paola A Torres, Matthew Swan, et al.
Drugs & Aging|October 19, 2023
Low-Income Older Adults' Vulnerability to Anticholinergic Medication-Associated FrailtyLana Sargent, Kristin M Zimmerman, Almutairi Mohammed, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 16, 2024
The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodiesKathryn A Wyman-Chick, Matthew J Barrett, Michael J Miller, et al.
CNS Neuroscience & Therapeutics|August 4, 2024
Determining the role of statins in Parkinson's disease risk reduction and disease modification: A comprehensive meta-analysis of 4 million participants' dataAbdelrahman Mady, Yehia Nabil, Asma Daoud, et al.
Systematic Reviews|November 4, 2025
Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trialsMoaz Elsayed Abouelmagd, Nereen A Almosilhy, Hamdy A Makhlouf, et al.
Annals of Clinical and Translational Neurology|April 15, 2020
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson diseaseDaniel Weintraub, Chelsea Caspell-Garcia, Tanya Simuni, et al.
Neurology and Therapy|May 8, 2024
Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for CliniciansKathryn A Wyman-Chick, Parichita Chaudhury, Ece Bayram, et al.
Pageof 8